Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Director Thomas Wilder of Penumbra Inc (NYSE:PEN), a medical devices company with a market capitalization of $10.07 billion, sold 372 shares of common stock on August 12, 2025, at a price of $240.16, for a total value of $89,339. The stock currently trades at $257.38, suggesting continued upward momentum since the transaction. According to InvestingPro analysis, Penumbra maintains a GREAT financial health score, though it currently trades above its Fair Value.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan. Following the transaction, Wilder directly holds 372 shares of Penumbra stock, with 4,506 shares held indirectly by the Thomas and Catharine Wilder Family Trust. A portion of the directly held shares is subject to vesting. InvestingPro subscribers can access 12 additional key insights about Penumbra, including detailed valuation metrics and growth projections through comprehensive Pro Research Reports, available for over 1,400 US stocks.
In other recent news, Penumbra Inc . reported its second-quarter 2025 earnings, surpassing expectations with an earnings per share (EPS) of $0.86, higher than the anticipated $0.83. The company also achieved a revenue of $339.5 million, exceeding the expected $327.77 million and marking a 13.4% year-over-year growth. Following these results, Penumbra raised its 2025 revenue guidance, attributing this to robust growth in its peripheral vascular segment and strong performance in its stroke business. Despite this positive financial performance, RBC Capital adjusted its price target for Penumbra to $325 from $330, maintaining an Outperform rating due to margin outlook considerations. UBS, on the other hand, raised its price target to $335 from $330, continuing to recommend a Buy rating on the stock, citing the company’s solid growth. These developments reflect a mixed response from analysts, highlighting differing perspectives on Penumbra’s future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.